Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
about
Tumor angiogenesis: pericytes and maturation are not to be ignoredMarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewTargeting angiogenesis in gynecologic cancersCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?More sound cancer therapy biomarker development with active noise control.Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysisCisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung CancerRandomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancerPhase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.Anti-angiogenic agents in the treatment of non-small cell lung cancer.Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 Loci on the risk and prognosis of portuguese patients with non-small cell lung cancer.Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal originTherapeutic advances in women's cancersBiomarkers in tumor angiogenesis and anti-angiogenic therapy.Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancerTargeted therapies for lung cancer: clinical experience and novel agentsBeyond antiangiogenesis: vascular modulation as an anticancer therapy-a reviewTargeted therapies in colorectal cancer-an integrative view by PPPMAnalysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.Improving Outcomes in Advanced Lung Cancer: Maintenance therapy in non-small-cell lung carcinoma.Novel compounds in the treatment of lung cancer: current and developing therapeutic agents.Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC)Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancerBiomarkers in advanced colorectal cancer: challenges in translating clinical research into practiceAn Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC).Emerging options for the management of non-small cell lung cancer.Blood-based biomarkers for the optimization of anti-angiogenic therapies
P2860
Q21296683-B946E476-3A36-4304-AF94-739F6C77E90DQ26752752-A60EED64-224C-4B13-B365-8AB40C88AE9BQ26824086-D16B8991-BB42-474B-83D5-AD2D7CC5A01CQ26824766-F83C06E2-FE11-449C-9572-CB03E972DADBQ26859144-3C97ABEF-D37F-4247-BA11-40B2DBDADFF0Q30442454-0DC1A99C-1540-4FFA-9513-45EA7B29BEA2Q30587082-952C5576-8FCE-4D0D-889D-CFFEEC92B551Q30616602-3D01ED47-EE45-43EC-8AD7-81703C391445Q30897591-C8140BD6-74F4-4415-B008-4A0713EE47D7Q33397464-6A287A9A-B01F-44EE-8A8C-8FB99EB80A4BQ33429242-0F64962C-2A2C-4AC0-906B-C48B8A7F37D6Q33598561-F28A2CA7-618E-447F-A037-A104704EDBE1Q34107482-6906273B-4467-4DF9-833F-7FB14A08B0A1Q34627959-046407F5-4868-4385-A96F-3814786AC274Q34724614-37AEE0F2-76EE-4E5B-80E2-B2A597976369Q34803030-D5B30EDC-BCDC-4579-BB1B-B4B31ECA0EA4Q34821321-1CB0CCE3-D967-4EA5-829A-F40B9CCB5A0BQ34854658-41A6722C-B460-4F80-B891-02DE04D60350Q34916352-A4C995AD-1F15-4EE6-9618-20F0E736A38DQ34988362-7AC2B4EE-8511-47B6-BB61-1879A0511E5DQ34989562-0D735008-E8D2-4A50-8AC9-83AF4721B4EBQ35057364-9BCF4831-DF5C-4866-887C-8FD0F602E83FQ35062862-418A3204-ACBD-49B3-BCCA-A6DF901C8CC0Q35144007-2CCF1C17-986F-4E8B-8C09-4ABDA7EB3EA1Q35377689-82E64D86-A5FA-4996-B579-E62174764FCCQ35418973-9E55AF4C-765B-4611-8049-A1C894AA85DBQ35536088-2912D7CA-DECA-411C-B1E7-B447D7493542Q35623279-8F21F250-CD97-4242-9C7E-5797BF93776FQ36054970-E475696B-1224-4547-A4F1-75431386CF56Q36061770-E8719805-87EE-43D6-AC4F-7F400D1768F8Q36646911-D1124010-3C01-4114-BF3B-EC69A9F6AFEBQ36714379-2F702C78-4E2F-44C4-BEB7-05CC8B48C048Q36741073-848C463B-03B0-4471-A866-5FBB35235CB6Q36890658-A8183E29-B097-4C2E-B4DC-DF287B27EBE0Q36996220-5CC3BE35-2253-4A1B-9A51-3E1CF4A08866Q37094898-EF9C05B6-E92B-4F1C-A2CB-92ABFDB295AEQ37132680-679C03DA-8C21-4E6E-A47D-D8E956460AEFQ37137440-52057CFB-7B29-4263-A5E8-25AF4B60C71FQ37269316-844496DF-5474-43C6-9EDE-7413F585BC2AQ37328390-804645EB-1359-48D7-AEE4-3717BDBE30F8
P2860
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical course of advanced no ...... n and paclitaxel on ECOG 4599.
@ast
Clinical course of advanced no ...... n and paclitaxel on ECOG 4599.
@en
type
label
Clinical course of advanced no ...... n and paclitaxel on ECOG 4599.
@ast
Clinical course of advanced no ...... n and paclitaxel on ECOG 4599.
@en
prefLabel
Clinical course of advanced no ...... n and paclitaxel on ECOG 4599.
@ast
Clinical course of advanced no ...... n and paclitaxel on ECOG 4599.
@en
P2093
P2860
P356
P1476
Clinical course of advanced no ...... n and paclitaxel on ECOG 4599.
@en
P2093
Alan B Sandler
David H Johnson
Joan H Schiller
Julie R Brahmer
Suzanne E Dahlberg
P2860
P304
P356
10.1200/JCO.2009.25.4482
P407
P577
2010-01-19T00:00:00Z